Navigation Links
PercSys Names David Auth and Howard Palefsky to Its Board of Directors

PALO ALTO, Calif., Oct. 16 /PRNewswire/ -- Percutaneous Systems, Inc. (PercSys) announced today that it has named two well known medical device entrepreneurs to its Board of Directors. They include David Auth, Ph.D., a medical device executive, educator, innovator and investor, and Howard Palefsky, a leading med-tech venture capitalist.

"PercSys is extraordinarily fortunate to gain the guidance of two of the legendary figures of the medical device industry," stated Robert S. Behl, PercSys founder and chief executive officer. "We look forward to working with these industry leaders as we seek to develop innovative solutions to serious medical problems."

Most recently, Dr. Auth has served as a board member and/or inventor with several medical device companies, including RadioTherapeutics and Novacept prior to their acquisitions, as well as Pathway Medical Technology, Coaptus, Medlogics, Mirabilis, Guided Delivery Systems, Arstasis, and Spineview. Previously, he founded Heart Technology Inc. in 1988 to commercialize his Rotablator invention. Heart Technology became a public company in 1992 and was acquired by Boston Scientific in 1995. Dr. Auth began his career as a professor of engineering at the University of Washington, where he became involved in the embryonic field of bioengineering. He and his graduate students performed seminal studies on multipolar radio frequency hemostasis and fast pulse thermal cautery, leading to the invention of three successful commercial products: the ACMI BICAP, the Olympus HPU, and the Novacept Novasure devices.

Mr. Palefsky has 35 years of experience as an entrepreneur and investor in medical device and pharmaceutical companies. He has been a general partner/managing member of Montreux Equity Partners since 2002 and was a venture partner of Montreux from 1999 to 2002. Prior to joining Montreux, he served as chairman and chief executive officer of NeurogesX. From 1978 to 1997, Mr. Palefsky was the chairman, president, chief executive officer and/or director of Collagen Corporation, guiding it from an early startup to a public company. During his tenure at Collagen, he made a number of successful corporate venture investments, including Target Therapeutics (subsequently sold to Boston Scientific). Mr. Palefsky currently serves on the boards of Windy Hill Medical, Avantis Medical Systems, PulmonX, and NovoStent, and previously held board positions with Questcor, Enteric Medical, and Pro-Duct before their initial public offering or acquisition.

About PercSys

PercSys is developing devices that make urologic and endoscopic procedures easier, less traumatic, and more effective therapeutically. The company is developing a series of unique products for endourology/treatment of kidney stones. The company's initial product, the PercSys Accordion(R) Stone Management Device, was introduced to the market in mid-2007, and a second device in the Accordion family was launched in 2008. Together, these two devices have been used successfully in over 800 endoscopic kidney stone treatments to date. For more information about PercSys and the PercSys Accordion Stone Management Device, please visit

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Board of Directors of Milestone Scientific Names Joseph DAgostino Chief Financial Officer
2. Horizon Therapeutics Names Robert J. De Vaere Executive Vice President and Chief Financial Officer
3. New England Peptide Names Director of Chemical Development
4. Codexis Names Vice President, Intellectual Property
5. Genstruct Names Louis Latino VP of Sales
6. Wyeth Names Daniel J. McIntyre Vice President, Corporate Communications
7. Axial Biotech Names New VP of Reimbursement and Regulatory Affairs
8. Inc. Magazine Names Senior Whole Health the Number One Fastest-Growing Private Company in US
9. ThermoGenesis Names Tiffany Olson to Board of Directors
10. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
11. eResearchTechnology Names New Chief Financial Officer
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... ... Amgen, will join the faculty of the University of North Carolina Kenan-Flagler ... of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on the school’s ...
(Date:6/24/2016)... discussions on a range of subjects including policies, debt and ... Poloz. Speaking at a lecture to the Canadian ... to the country,s inflation target, which is set by both ... "In certain areas there needs to be ... why not sit down and address strategy together?" ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:3/23/2016)... 2016 Einzigartige ... und Stimmerkennung mit Passwörtern     ... MESG ), ein führender Anbieter digitaler Kommunikationsdienste, ... SpeechPro zusammenarbeitet, um erstmals dessen Biometrietechnologie einzusetzen. ... Möglichkeit angeboten, im Rahmen mobiler Apps neben ...
(Date:3/22/2016)... and SANDY, Utah , March ... operates the highest sample volume laboratory in ... and UNIConnect, leaders in clinical sequencing informatics and molecular ... of a project to establish the informatics infrastructure for ... NSO has been contracted by the Ontario Ministry ...
(Date:3/18/2016)... LONDON , March 18, 2016 ... Established Suppliers of Biometrics, ICT, Manned & Unmanned Vehicles, Physical ... & security companies in the border security market and ... and Europe has led ... your companies improved success. --> defence & ...
Breaking Biology News(10 mins):